natgillin/translations-raw huggingface dataset:
The occurrence of suicidal behaviour is inherent in psychotic illnesses, and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8).
S psihozami je povezan tudi pojav samomorilnega vedenja, o katerem so v nekaterih primerih poročali kmalu po začetku antipsihotičnega zdravljenja, vključno z zdravljenjem z aripiprazolom (glejte poglavje 4.8).
• aggression
• agresija,
Multipack: Three single packages, each containing:
Skupno pakiranje: tri enojna pakiranja, vsako pakiranje vsebuje naslednje: Ena viala s praškom
Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and has moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic, and histamine H1 receptors.
Aripiprazol je imel v raziskavi in vitro veliko vezavno afiniteto za dopaminske receptorje D2 in D3 in za serotoninske receptorje 5-HT1A in 5-HT2A ter zmerno afiniteto za dopaminske receptorje D4, serotoninske receptorje 5-HT2C in 5-HT7, adrenergične receptorje alfa-1 in histaminske receptorje H1.
f) Slowly inject into the gluteal or deltoid muscle.
f) Počasi injicirajte v glutealno ali deltoidno mišico.
Vertically shake the syringe vigorously for 20 seconds until medicine is uniformly milky-white and use immediately.
Injekcijsko brizgo 20 sekund navpično močno stresajte, dokler zdravilo ni homogene, mlečno bele barve, in ga uporabite takoj za tem.
• an acutely agitated state or a severely psychotic state
• akutno agitirano stanje ali hudo psihotično stanje,
Your doctor will decide on the dose of Abilify Maintena that is right for you.
Zdravnik bo določil, kolikšen odmerek zdravila Abilify Maintena je za vas ustrezen.
• acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,
• akutno zmedenost, krče (epilepsijo), komo, kombinacijo povišane telesne temperature, hitrega dihanja, znojenja;
Full instructions for use and handling of Abilify Maintena are provided in the package leaflet (information intended for healthcare professionals).
Za celotna navodila o uporabi in ravnanju z zdravilom Abilify Maintena glejte navodila za uporabo (informacije za zdravstvene delavce).
Patients treated with aripiprazole should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki prejemajo aripiprazol, je treba opazovati za znaki in simptomi hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti), bolnike, ki imajo sladkorno bolezen ali dejavnike tveganja zanjo, pa redno spremljati, da bi odkrili poslabšanje uravnavanja glukoze (glejte poglavje 4.8).
There was a statistically significant treatment difference in favour of Abilify Maintena 400 mg/300 mg compared to placebo at week 10 (+7.1, p < 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).
Abilify Maintena 400 mg/300 mg v primerjavi s placebom v 10. tednu (+7,1, p < 0,0001, 95-odstotni IZ: 4,1, 10,1 z modelom ANCOVA (LOCF)).
a: Negative change in score indicates improvement.
Ni na voljo a: negativna sprememba ocene kaže na izboljšanje bolnikovega stanja.
g) Visually inspect the reconstituted suspension for particulate matter and discolouration prior to administration.
g) Rekonstituirano suspenzijo pred dajanjem preglejte za delci in obarvanjem.
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution.
Na podlagi preskušanj s peroralnim dajanjem aripiprazola se aripiprazol široko porazdeli po telesu in ima navidezni volumen porazdelitve 4,9 l/kg, kar kaže na izdatno zunajžilno distribucijo.
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day or approximately16 to 81 times the maximum recommended human dose based on mg/m2.
Dodaten izsledek je bila holelitiaza zaradi precipitacije sulfatnih konjugatov hidroksipresnovkov aripiprazola v žolču opic po ponavljajočem odmerjanju od 25 do 125 mg/kg/dan ali približno 16- do 81-kratni največji priporočeni odmerek za človeka glede na mg/m2.
This trial consisted of a screening phase and 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and Double-blind, Active-controlled Phase.
To preskušanje so sestavljale presejalna faza in tri faze zdravljenja: faza prehoda, faza peroralne stabilizacije in dvojno slepa s placebom nadzorovana faza.
Other medicines and Abilify Maintena
Druga zdravila in zdravilo Abilify Maintena
• thoughts about suicide
• samomorilne misli,
Your doctor or nurse will make it into a suspension that will be given as an injection using the vial of solvent for Abilify Maintena that comes as a clear solution in a clear glass vial.
Zdravnik ali medicinska sestra bo pripravil/-a suspenzijo, ki se injicira z vialo z vehiklom zdravila Abilify Maintena, ki je na voljo kot bistra raztopina v viali iz prozornega stekla.
No interaction studies have been performed with Abilify Maintena.
Študij medsebojnega delovanja z zdravilom Abilify Maintena niso izvedli.
The reconstituted medicine is a white to off-white, fluid suspension.
Rekonstituirano zdravilo je bela do belkasta tekoča suspenzija.
• decreased or increased blood levels of the hormone prolactin
• znižane ali zvišane vrednosti hormona prolaktina v krvi,
The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels.
Sočasni uporabi močnih induktorjev CYP3A4 z zdravilom Abilify Maintena se je treba izogibati, saj se raven aripiprazola v krvi zniža in lahko pade pod učinkovito raven.
When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain was more frequent in the deltoid muscle.
V primerjavi s študijami, v katerih je bilo zdravilo Abilify Maintena injicirano v glutealno mišico, je bila večkratna pojavnost bolečine na mestu injiciranja pogostejša pri injiciranju v deltoidno mišico.
• decreased or increased appetite
• povečan ali zmanjšan tek,
b) Select one of the following hypodermic safety needles depending on the injection site and patient's weight and attach the needle to the luer lock syringe containing the suspension for injection.
b) Glede na mesto injiciranja in telesno maso bolnika izberite eno od spodnjih varnostnih podkožnih igel in iglo pritrdite na injekcijsko brizgo z nastavkom Luer Lock, ki vsebuje suspenzijo za injiciranje.
• during tests your doctor may find higher amounts alkaline phosphatase fluctuating results during tests to measure glucose in your blood
• med testiranji lahko zdravnik ugotovi: zvišane količine alkalne fosfataze, nihanje med merjenji glukoze v krvi.
• if you have symptoms such as swelling, pain, and redness in the leg, because this may mean you have a blood clot, which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
• simptome, kot so otekanje, bolečina in pordelost kože na nogah, saj so lahko ti znak prisotnosti krvnih strdkov, ki lahko po krvnih žilah potujejo v pljuča in povzročijo bolečine v prsnem košu in težko dihanje.
After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days presumably due to absorption ratelimited kinetics.
Izločanje Po večkratnem odmerjanju zdravila Abilify Maintena 400 mg ali 300 mg je srednji razpolovni čas izločanja aripiprazola približno 46,5 dneva in 29,9 dneva, domnevno zaradi kinetike, omejene s hitrostjo absorpcije.
Injection site pain (incidence 5.1 %), had a median onset on day 2 after the injection and a median duration of 4 days.
Mediana časa do začetka bolečin na mestu injiciranja (pojavnost 5,1 %) je nastopila 2. dan po injiciranju, mediana trajanja pa je znašala 4 dni.
Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).
Na podlagi populacijske farmakokinetične analize zdravila Abilify Maintena je bil celotni telesni očistek aripiprazola 3,71 l/h pri osebah, ki dobro presnavljajo s CYP2D6 in približno 1,88 l/h (približno 50 % nižje) pri osebah, ki slabo presnavljajo sCYP2D6 (za priporočene odmerke glejte poglavje 4.2).
b Difference (Abilify Maintena minus placebo) in least squares mean change from baseline.
b Sprememba (Abilify Maintena minus placebo) povprečja najmanjših kvadratov od izhodišča.
Intramuscular use only
samo za intramuskularno uporabo
Additionally, it is known that the use of aripiprazole is associated with other ADR that may predispose to falls, such as somnolence, sedation, dizziness or hypotension.
Poleg tega je znano, da je uporaba aripiprazola povezana z drugimi neželenimi učinki, kot so somnolenca, sedacija, omotica ali hipotenzija, ki lahko povzročijo padce.
Add 1.9 ml solvent to reconstitute the powder.
Dodajte 1,9 ml vehikla, da rekonstituirate prašek.
300 mg vial:
300 mg viala:
The estimated proportion of patients experiencing impending relapse by end of Week 26 for Abilify Maintena was 7.12 %, which was statistically significantly lower than in aripiprazole Long-Acting Injectable 50 mg/25 mg (21.80 %; p = 0.0006).
Ocenjeno razmerje bolnikov, pri katerih se do konca 26. tedna pojavijo znaki bližnjega relapsa bolezni, je pri zdravilu Abilify Maintena znašalo 7,12 %, kar je bilo statistično bistveno nižje kot pri dolgodelujočem parantertalnem aripiprazolu 50 mg/25 mg (21,80 %; p = 0,0006).
The efficacy of Abilify Maintena in acutely relapsed adult patients with schizophrenia was established in a short-term (12-week), randomised, double-blind, placebo-controlled trial (n = 339).
Akutno zdravljenje shizofrenije pri odraslih bolnikih Učinkovitost zdravila Abilify Maintena pri odraslih bolnikih z akutnim relapsom shizofrenije so ugotavljali v kratkotrajnem (12-tedenskem), randomiziranem, dvojno slepem, s placebom nadzorovanem preskušanju (n = 339).
If you are receiving Abilify Maintena, your doctor will discuss with you whether you should breastfeed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding.
Če prejemate zdravilo Abilify Maintena, vam bo zdravnik pomagal pri odločitvi glede dojenja z upoštevanjem prednosti dojenja za otroka in prednosti zdravljenja za vas.
The front chamber between front stopper and middle stopper contains the powder and the rear chamber between middle stopper and end stopper the solvent.
Sprednja komora med sprednjim in srednjim zamaškom vsebuje prašek, zadnja komora med srednjim in končnim zamaškom pa vehikel.
Single pack
Skupno pakiranje
• increased blood fats such as high cholesterol, high triglycerides and also low level of cholesterol and low level of triglycerides
• povišane količine maščob v krvi, kot so holesterol, visoke vrednosti trigliceridov in nizke vrednosti holesterola in trigliceridov,
• heart problems including torsades de pointes, stopping of the heart, irregularities in heart rhythm that may be due to abnormal nerve impulses in the heart, abnormal readings during heart examination (ECG) QT prolongation
• težave s srcem, vključno s »torsades de pointes«, zastoj srca, nepravilnosti srčnega ritma, ki so lahko posledica normalnih živčnih impulzov v srcu, nenormalni odčitki pri srčnem pregledu
Contents of the pack and other information What Abilify Maintena contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Abilify Maintena
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Ledvična okvara Pri bolnikih z ledvično okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
Do not use this medicine after the expiry date which is stated on the carton and the pre-filled syringe.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in napolnjeni injekcijski brizgi.
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Klinični znaki MNS so hiperpireksija, mišična rigidnost, spremenjeno duševno stanje in znaki avtonomne labilnosti (nereden srčni utrip ali krvni tlak, tahikardija, čezmerno potenje in motnje srčnega ritma).
It should only be administered by a healthcare professional.
Zdravilo sme dajati samo zdravstveni delavec.
A small amount of excess product will remain in the vial.
Po tem bo v viali ostala majhna količina preostalega vehikla.
Taking into account the PRAC Assessment Report on the PSUR(s) for aripiprazole, the scientific conclusions of CHMP are as follows:
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za aripiprazol je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy.
Po prekinitvi uporabe zaviralca CYP2D6 ali CYP3A4 je treba odmerjanje aripiprazola povečati na raven, kakršna je bila pred uvedbo sočasne terapije.
400 mg vial:
400 mg viala:
Ensure the needle is firmly seated on the needle protection device with a push and clockwise twist and then pull the needle cap straight away from the needle.
Preverite, ali je igla čvrsto pritrjena na varnostnem pripomočku, tako da jo pritisnete in obrnete v desno, nato pa potegnite pokrovček naravnost stran od igle.
In case of adverse reactions despite dose adjustments of Abilify Maintena, the necessity of concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.
Če se kljub prilagoditvi odmerkov zdravila Abilify Maintena pojavijo neželeni učinki, je treba ponovno oceniti potrebo sočasnega jemanja zaviralcev CYP2D6 ali zaviralcev CYP3A4.
One vial of 2 ml solvent
Ena viala z 2 ml vehikla
After reconstitution each ml of suspension contains 200 mg aripiprazole.
Po rekonstituciji 1 ml suspenzije vsebuje 200 mg aripiprazola.
Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls.
Aripiprazol lahko povzroči somnolenco, posturalno hipotenzijo, motorično in senzorično nestabilnost,
h) If the injection is not performed immediately after reconstitution, keep the vial below 25 °C for up to 4 hours and shake it vigorously for at least 60 seconds to re-suspend prior to injection.
h) Če zdravila ne injicirate takoj po rekonstituciji, vialo hranite pri temperaturi do 25 °C največ štiri ure in jo pred injiciranjem močno stresajte vsaj 60 sekund, da ponovno suspendira.
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged.
V kliničnem preskušanju peroralnega aripiprazola pri zdravih preiskovancih je močan zaviralec CYP2D6 (kinidin) zvečal AUC aripiprazola za 107 %, njegova Cmax pa se ni spremenila.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures approximately 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose.
Razvojne toksične učinke, vključno z zapoznelo fetalno osifikacijo, odvisno od odmerka, in mogočimi teratogenimi učinki, so pri podganah opažali v odmerkih, ki so povzročili subterapevtsko izpostavljenost (na podlagi AUC), in pri kuncih v odmerkih, ki so povzročili izpostavljenost 3- in 11
Abilify Maintena with alcohol
Zdravilo Abilify Maintena skupaj z alkoholom
Subjects with akathisia typically received anti-cholinergic medicines as treatment, primarily benzatropine mesilate and trihexyphenidyl.
Preiskovanci z akatizijo so bili običajno zdravljeni z antiholinergičnimi zdravili, predvsem z benzatropin mesilatom in triheksifenidilom.
Weight gain is commonly seen in schizophrenic patients due to use of antipsychotics known to cause weight gain, co-morbidities, poorly managed life-style and might lead to severe complications.
Povečanje telesne mase je pri bolnikih s shizofrenijo pogosto zaradi uporabe antipsihotikov, za katere je znano, da povzročajo povečanje mase, komorbidnih stanj, neurejenega življenjskega sloga in lahko vodi do hudih zapletov.
The results of analysis of the primary efficacy endpoint, the estimated proportion of patients experiencing impending relapse by end of Week 26 of the Double-blind, Active-controlled Phase, showed that Abilify Maintena 400 mg/300 mg is non-inferior to aripiprazole oral tablets 10-30 mg.
Rezultati analize primarne končne točke učinkovitosti in ocenjeno razmerje bolnikov, pri katerih se do konca 26. tedna dvojno slepe aktivno nadzorovane faze pojavijo znaki bližnjega relapsa bolezni, kažejo, da je zdravilo Abilify Maintena 400 mg/300 mg neinferiorno zdravilu aripiprazol v 10-30 mg peroralnih tabletah.
If your baby develops any of these symptoms you need to contact your doctor.
Če se pri vašem otroku pojavi kateri od teh simptomov, se posvetujte z zdravnikom.
Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section 4.5).
Sočasni uporabi močnih induktorjev CYP3A4 in zdravila Abilify Maintena več kot 14 dni se je treba izogibati, saj se raven aripiprazola v krvi zniža in lahko pade pod učinkovito raven (glejte poglavje 4.5).
Deltoid injections should be alternated between the two deltoid muscles.
Injiciranje v deltoidno mišico je treba izmenjevati med obema deltoidnima mišicama.
These included: dose-dependent adrenocortical toxicity in rats after 104 weeks of oral administration at approximately 3 to 10 times the mean steady-state AUC at the maximum recommended human dose and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at approximately 10 times the mean steady-state AUC at the maximum recommended human dose.
adrenokortikalni toksični učinki pri podganah, odvisni od odmerka, po 104 tednih oralnega odmerjanja od 3- do 10-kratne srednje AUC ob največjem priporočenem odmerku za človeka ter povečana pogostnost adrenokortikalnih karcinomov in kombiniranih adrenokortikalnih adenomov/karcinomov pri podganjih samicah ob odmerjanju približno 10-kratno srednjo AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka.
Step 2: Reconstitution of the powder a) Remove the solvent and powder vial caps and wipe the tops with a sterile alcohol swab.
Korak 2: Rekonstitucija praška a) Odstranite pokrovček viale z vehiklom in viale s praškom ter vrhnje dele obrišite s sterilno alkoholno blazinico.
In a single-dose study with oral administration of aripiprazole, the pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to that in young healthy subjects.
Ledvična okvara Študija z enim samim odmerkom oralnega aripiprazola kaže, da so farmakokinetične lastnosti aripiprazola in dehidroaripiprazola pri bolnikih s hudo boleznijo ledvic podobne kot pri mladih zdravih preiskovancih.
Receiving Abilify Maintena with some medicines may mean the doctor will need to change your dose of Abilify Maintena or the other medicines.
Pri jemanju zdravila Abilify Maintena skupaj z nekaterimi drugimi zdravili bo morda treba spremeniti odmerek zdravila Abilify Maintena.
One vial of powder
Ena viala s praškom
With intramuscular injection, however an inflammatory response was seen at the injection site, and consisted of granulomatous inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling) and, in monkeys, fibrosis.
Pri intramuskularnem injiciranju so opazili vnetno reakcijo na mestu injiciranja, ki je vključevala granulomatozno vnetje, žarišča (ostanke zdravila), celične infiltrate, edem (oteklino) in fibrozo pri opicah.
A number of symptoms of dystonia are then listed, including spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
Nato so navedeni številni simptomi distonije, vključno s krčem vratnih mišic, ki včasih napreduje v stiskanje žrela, težave pri požiranju, težave z dihanjem in/ali protruzijo jezika.
However, in one of these trials, a fixed-dose trial, there was a significant doseresponse relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Toda v enem od teh preskušanj (preskušanje s fiksnim odmerkom) je pri bolnikih, ki so prejemali aripiprazol, za cerebrovaskularne neželene učinke obstajal pomemben odnos med odmerkom in odzivom (glejte poglavje 4.8).
• allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash
• alergijska reakcija (npr. oteklost ust, jezika, obraza in žrela, srbenje, koprivnica), izpuščaj,
Step 1: Preparation prior to reconstitution of the powder Lay out and confirm that components listed below are provided: - Abilify Maintena package leaflet and instructions for healthcare professionals.
Korak 1: Priprava pred rekonstitucijo praška Pripravite komponente in preverite, ali so prisotne vse naslednje: - navodila za uporabo zdravila Abilify Maintena in navodila za zdravstveno osebje, - viala s praškom, - viala z vehiklom 2 ml,
Proportion of subjects free of impending relapse
Delež oseb brez tveganja za pojav skorajšnjega relapsa
The safety profile was consistent with that known to Abilify Maintena.
Varnostni profil ustreza že znanemu profilu za zdravilo Abilify Maintena.
• thirstiness more than usual, need to urinate more than usual, feel very hungry, feel weak or tired, feel sick, feel confused or your breath smells fruity, since this may be a sign of diabetes.
• močnejšo žejo kot običajno, močnejšo potreba po uriniranju kot običajno, občutek močne lakote, občutek šibkosti ali utrujenosti, občutek slabosti, občutek zmedenosti ali zadah z vonjem po sadju, saj je to lahko znak sladkorne bolezni.
Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reduction should, therefore, be applied (see section 4.2).
Pričakovati je mogoče, da imajo drugi močni zaviralci CYP2D6, npr. fluoksetin in paroksetin, podobne učinke, zato je treba odmerek zmanjšati v podobni meri (glejte poglavje 4.2).
The estimated relapse rate by end of Week 26 was 7.12 % for Abilify Maintena, and 7.76 % for oral aripiprazole tablets 10-30 mg, a difference of -0.64 %.
Ocenjena stopnja relapsa bolezni do konca 26. tedna je bila 7,12 % pri zdravilu Abilify Maintena, in 7,76 % pri aripiprazolu v 10-30 mg peroralnih tabletah, z razliko −0,64 %.
Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2).
Pričakovati je mogoče, da imajo drugi močni zaviralci CYP3A4, npr. itrakonazol in zaviralci proteaz HIV, podobne učinke, zato je treba odmerke zmanjšati v podobni meri (glejte poglavje 4.2).
If you are given more Abilify Maintena than you should
Če ste dobili večji odmerek zdravila Abilify Maintena, kot bi smeli
- The active substance is aripiprazole.
- Zdravilna učinkovina je aripiprazol.
• blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots
• krvne strdke ali težave s krvnimi strdki v družini; antipsihotike namreč povezujejo z nastajanjem krvnih strdkov,